Purpose: To describe the retinal findings associated with pemigatinib, an oral competitive inhibitor of fibroblast growth factor receptor (FGFR) approved for the treatment of cholangiocarcinoma.
Methods: We present a case report and performed a literature review, revealing only two prior reported cases of pemigatinib-mediated subretinal fluid.
Results: A 72-year-old woman presented with transient visual symptoms while on pemigatinib for the treatment of cholangiocarcinoma. Optical coherence tomography (OCT) revealed subfoveal subretinal fluid bilaterally that resolved during a drug holiday, however fluctuated throughout her treatment course. She remained on pemigatinib for ten months without other ocular sequelae.
Conclusions: This is one of the few reported cases of pemigatinib-related retinopathy, which further supports the self-limited and benign nature of subretinal fluid associated with FGFR inhibitors.